CENTENNIAL, Colo. (SEND2PRESS NEWSWIRE) — Cell>Point announced today that M. Donald Blaufox, M.D., Ph.D, will be coordinating principal investigator for its Phase 2/3 clinical trial of 99mTc-EC-G for cancer diagnostic imaging. The trial is currently underway.
99mTc-EC-G is the company’s cancer diagnostic imaging agent, an acronym for 99mTechnetium-EthylenediCysteine-Glucosamine.
“We are honored to have the support and cooperation from a physician with the recognized stature of Dr. Blaufox,” said Greg Colip, Cell>Point CEO. “He’s a founder and leader in nuclear medicine.”
Blaufox will present clinical trial findings at select upcoming medical conferences.
Blaufox is founding Chairman of the Department of Nuclear Medicine at Albert Einstein College of Medicine and Montefiore Medical Center.
Among his many other credentials are:
* Former chairman and lifetime member American Board of Nuclear Medicine
* Principal investigator Hypertension Detection and Follow-up program (Lasker Award recipient)
* Clinical trials review committee National Heart, Lung and Blood Institute
* 293 peer-review articles and chapters
* 25 medical texts
* Editorial board six journals
* Co-editor Seminars in Nuclear Medicine, Yearbook of Nuclear Medicine
* Numerous named lectures and international awards
* Honorary Professor of Medicine, Shanxi University School of Medicine, Taiyuan, China
* Founding chairman Nuclear Medicine Section, New York Academy of Medicine.
Montefiore Medical Center is one of six clinical trial sites for the 99mTc-EC-G cancer trial. Others are John Hopkins University, Mayo Clinic, Baptist Health South Florida, Decatur Memorial Hospital, and British Columbia Medical Center in North Vancouver, Canada. Blaufox is also principal investigator of the Montefiore site.
The Phase 2/3 clinical trial compares 99mTc-EC-G (administered and then imaged with a SPECT camera) to 18F-FDG (administered and then imaged with a PET camera) in the evaluation of patients with non-small cell lung cancer. More information on the trial can be found at www.clinicaltrials.gov. Trial identifier is NCT00865319.
More information on 99mTc-EC-G can be found at the Cell>Point Website (www.cellpointweb.com) under TechnologyPipeline.
18F-FDG is FluoroDeoxyGlucose. Used in the medical imaging modality Positron Emission Tomography (PET), it is the current standard in diagnosing, staging, and monitoring treatment of cancers.
SPECT is Single Photon Emission Computed Tomography. SPECT cameras are 25-fold more prevalent than, and one-quarter the cost of, PET cameras. Radiation from a 99mTc-EC-G SPECT procedure is as much as 75 percent less than that of an 18F-FDG PET procedure.
Cell>Point is a clinical-stage biopharmaceutical company developing universal molecular imaging agents and molecular therapeutics for the diagnosis, treatment and treatment monitoring of cancer, heart, and other diseases. Cell>Point has exclusive license to five drug-development platforms, all from The University of Texas M. D. Anderson Cancer Center in Houston, a world leader in cancer research and care. Information on Cell>Point’s drug candidates, recent press releases, and patents and patent filings can be obtained through its Website at www.cellpointweb.com . The company is headquartered in Centennial, Colo., and has additional offices in San Francisco and Houston.
News Source: Cell Point LLC
This story was issued by Send2Press® and is Copyright © 2010 Neotrope® News Network – all rights reserved.